Ownership and insider activity for Immunovant, Inc. (IMVT): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases.
Price
| Price | $28.41 (closing price, November 2, 2026) |
| Market Cap | $5.9B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-28 | Girao Tiago | S-Sale | 6,606 | $188K |
| 2026-10-21 | Stout Jay S | S-Sale | 2,595 | $75K |
| 2026-10-07 | Stout Jay S | S-Sale | 2,213 | $71K |
| 2026-10-07 | Stout Jay S | S-Sale | 1,596 | $51K |
| 2026-10-07 | Van Tuyl Christopher | S-Sale | 1,327 | $43K |
| 2026-10-07 | Gloria Melanie | S-Sale | 2,241 | $72K |
| 2026-10-01 | Venker Eric | M-Exempt | 92,187 | $1.3M |
| 2026-10-01 | Venker Eric | M-Exempt | 92,187 | $1.3M |
| 2026-10-01 | Venker Eric | D-Return | 85,886 | $2.9M |
| 2026-10-02 | Venker Eric | S-Sale | 3,506 | $120K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 0 | $325,000 | $100.6M | $400.1M | $493.8M | $376.5M | $635.4M | $714.0M | $902.1M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | $3.0M | $1.1M | $12.9M | $885,000 | $5.5M | $2.5M | $3.9M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $113,170 | $325,000 | $109.1M | $409.0M | $512.9M | $404.3M | $665.8M | $767.7M | $948.8M |
| Property, Plant & Equipment | 0 | 0 | $65,000 | $3.5M | $2.6M | $1.5M | $595,000 | $942,000 | $515,000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $113,170 | $405,000 | $109.4M | $412.5M | $515.6M | $405.8M | $666.7M | $776.2M | $957.6M |
| Accounts Payable | $1.1M | 0 | $1.2M | $2.4M | $18.6M | $1.4M | $7.2M | $17.7M | $7.5M |
| Short-term Debt | 0 | $300,000 | $3.2M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.6M | $380,448 | $15.3M | $18.8M | $44.5M | $43.3M | $48.6M | $68.8M | $104.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.6M | $380,448 | $15.3M | $21.0M | $45.7M | $43.3M | $49.0M | $68.8M | $105.0M |
| Retained Earnings | 0 | -$448 | -$91.2M | -$198.7M | -$355.4M | -$566.3M | -$825.7M | -$1.24B | -$1.75B |
| Total Equity | -$1.5M | $24,552 | $94.1M | $391.5M | $469.8M | $362.5M | $617.8M | $707.4M | $852.6M |
| Total Debt | 0 | $300,000 | $3.2M | $3.4M | $2.4M | $1.2M | $138,000 | $98,000 | $72,000 |
| Net Debt | 0 | -$25,000 | -$97.4M | -$396.7M | -$491.5M | -$375.3M | -$635.2M | -$713.9M | -$902.0M |
| Working Capital | -$1.5M | -$55,448 | $93.8M | $390.2M | $468.4M | $361.0M | $617.2M | $698.9M | $844.4M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 7.27 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 22.57 |
Profitability
| Return on Equity | -69.59% |
| Return on Invested Capital | -75.90% |
| Return on Assets | -63.13% |
| Gross Margin | 97.10% |
| Operating Margin | -7,877.46% |
| Net Margin | -7,585.86% |
Related companies: TGTX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of IMVT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks